Simulations Plus Reports Third Quarter Fiscal 2026 Financial Results

Simulations Plus reported Q3 FY2026 revenue of $21.9 million, up 7% year over year, indicating modest growth. Software revenue was flat at $12.6 million and comprised 58% of total revenue. Overall, the results point to a mild positive earnings momentum without clear evidence of acceleration.

Analysis

The important read-through is not the modest top-line growth itself, but the composition: if software is not accelerating, the market should assume less recurring revenue leverage and more dependence on lower-multiple services or implementation work. That tends to cap valuation expansion in niche life-science software names because investors pay up for sticky ARR, not project-based revenue. In a tighter biotech funding backdrop, customers may be deferring software seat expansion while still using advisory-style engagements, which is supportive near term but weaker for the medium-term multiple.

For competitive dynamics, this is a relative negative versus higher-recurring peers such as CERT and, to a lesser extent, other workflow/analytical software names that can show clearer subscription traction. If SLP’s AI narrative is real, it should start showing up first in software growth and gross margin, not just total revenue; otherwise AI is still mostly a branding lever. The contrarian view is that the market may over-penalize a single quarter of flat software if billings and renewals are intact, because this business can inflect late-cycle once pharma spending normalizes.

Time horizon matters: over days, this is probably a small reaction stock; over 1-3 months, the catalyst is whether management can prove that software is re-accelerating or whether growth is being padded by services; over 6-18 months, the key question is whether SLP earns a premium multiple versus CERT or stays a lower-quality compounder. What would falsify the bearish read is a clear inflection in software bookings/ARR and margin expansion next quarter; absent that, the risk is gradual multiple compression rather than a sharp drawdown.

Key Decisions for Investors

• No immediate directional trade in SLP on this print; treat as a watch item until management discloses software bookings/ARR and gross margin trend.
• If SLP rallies >5-7% on the release without a software re-acceleration, consider fading strength with a small short for a 1-3 month mean-reversion setup; thesis breaks if next quarter software growth re-accelerates meaningfully.
• Relative value: long CERT / short SLP over 1-3 months if CERT continues to show stronger recurring revenue and SLP remains mix-heavy toward services; target 10-15% spread move, exit if SLP prints improving software growth >10%.
• For longer-term investors, buy SLP only on a post-earnings pullback of ~8-10% if guidance is unchanged and margins hold; that offers a better risk/reward than paying up into an uncertain AI monetization story.